Curis Inc.

NASDAQ: CRIS · Real-Time Price · USD
2.48
0.37 (17.54%)
At close: May 01, 2025, 3:59 PM
2.49
0.40%
After-hours: May 01, 2025, 05:56 PM EDT
17.54%
Bid 1.87
Market Cap 25.95M
Revenue (ttm) 10.91M
Net Income (ttm) -43.39M
EPS (ttm) -6.88
PE Ratio (ttm) -0.36
Forward PE -0.52
Analyst Buy
Ask 2.5
Volume 263,053
Avg. Volume (20D) 59,185
Open 2.24
Previous Close 2.11
Day's Range 2.32 - 2.66
52-Week Range 1.02 - 16.99
Beta 3.51

About CRIS

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize t...

Industry Biotechnology
Sector Healthcare
IPO Date Aug 1, 2000
Employees 34
Stock Exchange NASDAQ
Ticker Symbol CRIS
Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for CRIS stock is "Buy." The 12-month stock price forecast is $21, which is an increase of 746.77% from the latest price.

Stock Forecasts

Next Earnings Release

Curis Inc. is scheduled to release its earnings on May 6, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription